Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: The lawsuits were the latest by states and local governments against drugmaker Purdue Pharma as the country grapples with an opioid epidemic. About a dozen states have also targeted Richard Sackler, the company’s former leader, or members of his family. “Purdue and the Sacklers traded the health and well-being of Californians for profit and created an unprecedented national public health crisis in the process,” California Attorney General Xavier Becerra said at a news conference announcing the legal action by his state. “We will hold them accountable.” Becerra, echoing allegations lodged against Purdue Pharma by others attorneys general across the country, said the company falsely introduced OxyContin in the 1990s as a safe and effective treatment for chronic pain. However, the California’s lawsuit alleges that Purdue and Sackler knew in 1997 that drugs containing oxycodone, such as OxyContin, were widely abused. Still, company representatives marketed it as not being addictive and downplayed the potential for abuse, the suit states. In a statement Monday, Purdue Pharma and former directors of the company denied the allegations and vowed to defend against the “misleading attacks.” It noted that OxyContin represents less than 2% of total opioid prescriptions and is still approved by the U.S. Food and Drug Administration for its intended use as a painkiller as prescribed by doctors and dispensed by pharmacists. “Such allegations demand clear evidence linking the conduct alleged to the harm described,” spokesman Robert Josephson said in a statement. “But we believe the state fails to show such causation and offers little evidence to support its sweeping legal claims.” A spokesman for Sackler did not immediately respond to a request for comment. The family has faced a backlash in recent years amid a growing public outcry around opioid addiction. In addition, activists have targeted institutions, such as the Metropolitan Museum of Art, that the family has supported through large contributions. The museum has said it will no longer take money from members of the family linked to the drugmaker. Purdue stopped marketing OxyContin to doctors last year. It settled a lawsuit by the state of Oklahoma in March for $270 million. The company previously said it is pursuing several options, including bankruptcy, which could upend pending litigation by states as well as about 2,000 local and tribal governments across the country. The lawsuits filed Monday allege that Purdue Pharma pushed doctors to prescribe opioids for longer periods of time at higher doses. “Our complaint alleges that their unrelenting sales visits to doctors and deceptive practices led to a marked increase in opioid prescriptions, and a corresponding increase in the number of Mainers suffering from opioid use disorder,” Maine Attorney General Aaron M. Frey said. Maine’s lawsuit names Richard Sackler, Jonathan Sackler, Mortimer D.A. Sackler and Kathe Sackler — all of whom have served on the board of Stamford, Connecticut-based Purdue Pharma. States have also cracked down on doctors who overprescribe the drug. Hawaii Attorney General Clare Connors said in a statement Monday that she has filed lawsuits alleging violations of Hawaii’s Unfair and Deceptive Acts and Practices Law. One complaint alleges Purdue deceptively marketed OxyContin and other opioids. Another says manufacturers and distributors sold more opioids than could be “legitimately prescribed.” Meanwhile, the Centers for Disease Control and Prevention said opioids are the main driver of drug overdose deaths. Opioids were involved in 47,600 overdose deaths in the U.S. in 2017, according to the agency. In 2017, it says, prescription opioids were involved in 1,172 overdose deaths in California; 100 overdose deaths in Maine; and 58 in the District of Columbia. Maine set a state record for total drug overdose deaths in 2017 with 417. Jordan Basileu joined Becerra in announcing California’s lawsuit. He said he was prescribed opioid painkillers at 18 following a car crash and became addicted. “People think, ‘it’s from a doctor. How bad can it be?’” Basileu said of the drug. Basileu said he overdosed four times before getting sober three years ago. “I’m still cleaning up the mess that opioids got me in to,” he said. ___ Associated Press reporters Adam Beam and Caleb Jones contributed to this story. Jones reported from Honolulu. Claim: More states sue opioid maker alleging deceptive marketing.
[EX A]: California, Hawaii, Maine and the District of Columbia filed lawsuits Monday against the maker of OxyContin and the company’s former president, alleging the firm falsely promoted the drug by downplaying the risk of addiction while it emerged as one of the most widely abused opioids in the U.S.

[EX Q]: Paragraph: A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville The GlaxoSmithKline Plc vaccine Rotarix fights infection with the rotavirus, which causes about 55,000 hospitalizations in U.S. children each year and kills more than 600,000 children worldwide, mostly in developing countries. Rotarix already is approved in more than 100 other countries throughout the world. The vaccine competes with Merck & Co Inc’s rotavirus vaccine called RotaTeq. Without vaccination, nearly every child in the United States likely would be infected at least once with rotavirus by age five, the Food and Drug Administration said. In studies of more than 24,000 infants, Rotarix prevented severe and mild cases of rotavirus-caused diarrhea and vomiting during the first two years of life. “This vaccine provides another option to combat and reduce a potentially severe illness that affects so many children,” Dr. Jesse Goodman, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement announcing the Rotarix approval. The most common reactions reported during clinical trials were fussiness, irritability, cough, runny nose, fever, loss of appetite and vomiting, the FDA said. An earlier oral rotavirus vaccine sold by Wyeth was pulled from the market in 1999 after it was linked to a rare, life-threatening type of bowel obstruction known as intussusception. In a Glaxo study of more than 63,000 infants, there was no increase in the problem compared with a placebo. Higher rates of convulsion and pneumonia-related deaths were seen in Rotarix patients in that study but not in other Glaxo trials. “Although the FDA has concluded that the available data do not establish that these events are related to the vaccine, the agency has requested the manufacturer to conduct post-marketing safety studies involving more than 40,000 infants to provide additional safety information,” the FDA said. Glaxo said Rotarix “will offer protection against the most commonly circulating rotavirus types in the U.S. and allow infants to complete the vaccination series by four months of age.”   Rotarix, which is a liquid, is given in two doses to infants from six to 24 weeks of age, the FDA said. Merck’s RotaTeq vaccine is administered in three doses from ages six weeks to 32 weeks. Sales of Rotarix were $182 million in 2007 and are expected to rise with approval in the large U.S. market. The vaccine will be commercially available in the United States in the second half of the year, Glaxo said. Also on Thursday, researchers reported that Rotarix provided protection for up to two years in a study of infants from 10 Latin American countries. The Glaxo-funded trial of more than 15,000 infants found severe diarrhea from rotavirus in 0.4 percent of children given the vaccine, compared with 2.3 percent in the placebo group. Results were published in the Lancet medical journal. The arrival of a new generation of oral vaccines against the disease has been welcomed by health-care workers, but some experts caution against assuming the vaccines will work equally well in all countries. In a commentary in the Lancet, Australian pediatric experts Keith Grimwood and Carl Kirkwood noted Rotarix was more effective in European trials than in middle-income Latin American countries. The World Health Organization “is awaiting efficacy data from low-income countries of Africa and Asia, where much greater strain diversity exists and where 413,000 deaths occur every year compared with 15,000 in Latin America and 200 in Europe,” Grimwood and Kirkwood wrote. Claim: Glaxo wins FDA clearance for rotavirus vaccine.
[EX A]: A second oral vaccine to prevent a leading cause of severe diarrhea in infants won approval from U.S. health officials on Thursday.

[EX Q]: Paragraph: The burials, found underneath the cremated remains of an Ice Age toddler, date to about 11,500 years ago and provide new insights into mortuary practices of the people who lived in the area of the Upward Sun River site at the time. The largely complete skeletons were found in a circular pit with associated “grave goods” that included four antler rods and two stone projectile points, all decorated with red ochre, according to research carried out last year by a team led by University of Alaska anthropologist Ben Potter. In a paper published on Monday in the Proceedings of the National Academy of Sciences, the team said skeletal and dental analyses indicate one of the skeletons was of an infant that died shortly after birth, while the other was of a late-term fetus. The site represents the youngest-aged late Pleistocene individuals known in the Americas, it said, as well as the continent’s only known prenatal burial dating from the period. The pair, both tentatively believed to have been female, were found buried about 16 inches (40 cm) beneath the cremated remains of a 3-year-old child that was previously excavated by the team during work at the site in 2010. “Two interred infants with associated grave goods and a third cremated child represent the earliest known human remains from the North American subarctic, and they provide evidence for novel mortuary behaviors at the end of the last Ice Age,” the authors wrote. The team, which included Joel Irish of Liverpool John Moores University, said the site shares characteristics with other burials from the same periods, including interment in pits, red ochre, and grave goods consisting of functional tools, as opposed to ornaments or trinkets. The archaeologists believe the stone projectile points were once attached to the antler rods to make tools or weapons, and could reflect the importance of hunting implements in the burial ceremony. But they said they also noted the predominance of fish and small game remains at the site. Claim: Scientists find rare burial site of Ice Age infant in Alaska.
[EX A]:
Archaeologists working in Alaska’s remote interior have discovered the burial site of an Ice Age infant and a late-term fetus believed to be the youngest remains found in the Americas dating from that period.

